CN102770024A - 4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式 - Google Patents

4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式 Download PDF

Info

Publication number
CN102770024A
CN102770024A CN2011800099967A CN201180009996A CN102770024A CN 102770024 A CN102770024 A CN 102770024A CN 2011800099967 A CN2011800099967 A CN 2011800099967A CN 201180009996 A CN201180009996 A CN 201180009996A CN 102770024 A CN102770024 A CN 102770024A
Authority
CN
China
Prior art keywords
crystal form
cancer
ray powder
powder diffraction
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800099967A
Other languages
English (en)
Chinese (zh)
Inventor
伊恩·阿米蒂奇
马丁·I·库珀
马克·D·爱德斯顿
尼尔·C·法贝尔
昆廷·J·麦卡宾
斯蒂芬·W·瓦特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN102770024A publication Critical patent/CN102770024A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN2011800099967A 2010-02-19 2011-02-15 4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式 Pending CN102770024A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30604710P 2010-02-19 2010-02-19
US61/306,047 2010-02-19
PCT/US2011/024883 WO2011103089A1 (en) 2010-02-19 2011-02-15 Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410055631.3A Division CN104031049A (zh) 2010-02-19 2011-02-15 极光激酶抑制剂的结晶形式

Publications (1)

Publication Number Publication Date
CN102770024A true CN102770024A (zh) 2012-11-07

Family

ID=44483264

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410055631.3A Pending CN104031049A (zh) 2010-02-19 2011-02-15 极光激酶抑制剂的结晶形式
CN2011800099967A Pending CN102770024A (zh) 2010-02-19 2011-02-15 4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201410055631.3A Pending CN104031049A (zh) 2010-02-19 2011-02-15 极光激酶抑制剂的结晶形式

Country Status (8)

Country Link
US (3) US8653064B2 (enExample)
EP (1) EP2536279A4 (enExample)
JP (2) JP2013520424A (enExample)
CN (2) CN104031049A (enExample)
BR (1) BR112012020557A8 (enExample)
CA (1) CA2788774A1 (enExample)
RU (1) RU2012140021A (enExample)
WO (1) WO2011103089A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103408551A (zh) * 2013-07-25 2013-11-27 苏州明锐医药科技有限公司 阿立塞替的制备方法
CN103408552A (zh) * 2013-07-25 2013-11-27 苏州明锐医药科技有限公司 阿立塞替的制备方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5738196B2 (ja) * 2008-12-22 2015-06-17 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
RU2012140021A (ru) 2010-02-19 2014-03-27 Миллениум Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103724350A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
US20180207173A1 (en) 2015-07-21 2018-07-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747487A (en) * 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
CN101014603A (zh) * 2004-05-14 2007-08-08 千禧药品公司 通过抑制极光激酶抑制有丝分裂的化合物和方法
US20070185087A1 (en) * 2004-05-14 2007-08-09 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression
CN101547924A (zh) * 2006-11-16 2009-09-30 米伦纽姆医药公司 抑制有丝分裂的化合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
CA1138863A (en) 1979-02-07 1983-01-04 Norman W. Gilman Benzazepine-derivatives
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0888350A1 (en) 1996-03-08 1999-01-07 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
IL135303A0 (en) 1997-09-29 2001-05-20 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives, process for producing the same and antiallergic agents
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
CN100389825C (zh) 1999-08-11 2008-05-28 拜奥根Idec公司 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
ATE354573T1 (de) 2000-12-21 2007-03-15 Vertex Pharma ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
CN100418955C (zh) 2001-08-09 2008-09-17 埃科特莱茵药品有限公司 新型苯并稠杂环
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
MX2007005857A (es) 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
US20070104785A1 (en) 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
MX2008008320A (es) 2005-12-23 2008-09-03 Smithkline Beecham Corp Inhibidores de azaindol de aurora cinasas.
CA2656393A1 (en) 2006-06-30 2008-01-10 Schering Corporation Method of using substituted piperidines that increase p53 activity
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
JP5738196B2 (ja) 2008-12-22 2015-06-17 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
RU2012140021A (ru) 2010-02-19 2014-03-27 Миллениум Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747487A (en) * 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
CN101014603A (zh) * 2004-05-14 2007-08-08 千禧药品公司 通过抑制极光激酶抑制有丝分裂的化合物和方法
US20070185087A1 (en) * 2004-05-14 2007-08-09 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression
US7572784B2 (en) * 2004-05-14 2009-08-11 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression
US20090299060A1 (en) * 2004-05-14 2009-12-03 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression
CN101547924A (zh) * 2006-11-16 2009-09-30 米伦纽姆医药公司 抑制有丝分裂的化合物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103408551A (zh) * 2013-07-25 2013-11-27 苏州明锐医药科技有限公司 阿立塞替的制备方法
CN103408552A (zh) * 2013-07-25 2013-11-27 苏州明锐医药科技有限公司 阿立塞替的制备方法
CN103408552B (zh) * 2013-07-25 2015-07-01 苏州明锐医药科技有限公司 阿立塞替的制备方法
CN103408551B (zh) * 2013-07-25 2015-08-05 苏州明锐医药科技有限公司 阿立塞替的制备方法

Also Published As

Publication number Publication date
EP2536279A1 (en) 2012-12-26
RU2012140021A (ru) 2014-03-27
CA2788774A1 (en) 2011-08-25
BR112012020557A2 (pt) 2015-12-08
US20170190706A1 (en) 2017-07-06
US8653064B2 (en) 2014-02-18
BR112012020557A8 (pt) 2018-01-02
US10017513B2 (en) 2018-07-10
US20110245234A1 (en) 2011-10-06
JP2015180679A (ja) 2015-10-15
EP2536279A4 (en) 2013-07-24
CN104031049A (zh) 2014-09-10
WO2011103089A1 (en) 2011-08-25
US20140357622A1 (en) 2014-12-04
JP2013520424A (ja) 2013-06-06

Similar Documents

Publication Publication Date Title
US10017513B2 (en) Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate
CN112805281B (zh) Kras g12c抑制剂
CN114846006B (zh) 杂环化合物及其制备方法和用途
JP6676602B2 (ja) 上皮成長因子受容体キナーゼ阻害剤の塩
TWI698428B (zh) Mdm2抑制劑之製備方法及結晶型
JP5916752B2 (ja) ５−クロロ−ｎ２−（２−イソプロポキシ−５−メチル−４−ピペリジン−４−イル−フェニル）−ｎ４［２−（プロパン−２−スルホニル）−フェニル］−ピリミジン−２，４−ジアミンの結晶形
US7872020B2 (en) TGF-β inhibitors
TWI704151B (zh) Ｅｒｋ抑制劑
JP6918824B2 (ja) ２−［（２Ｓ）−１−アザビシクロ［２．２．２］オクタ−２−イル］−６−（３−メチル−１Ｈ−ピラゾール−４−イル）チエノ［３，２−ｄ］ピリミジン−４（３Ｈ）−オン半水和物の結晶形
KR102480074B1 (ko) 설폰아마이드 화합물 및 이의 용도
TWI675839B (zh) 一種ｊａｋ激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法
CN102421780A (zh) 氨基磺酸((1s，2s，4r)-4-{4-[(1s)-2，3-二氢-1h-茚-1-基氨基]-7h-吡咯并[2，3-d]嘧啶-7-基}-2-羟基环戊基)甲酯盐酸盐
CA2829939A1 (en) Tricyclic gyrase inhibitors
WO2016090257A1 (en) Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
CN104520297B (zh) 作为肾酪氨酸激酶抑制剂的双环杂芳基环烷基二胺衍生物
TWI796250B (zh) 經取代之 5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式
WO2018028491A1 (zh) 吲哚胺2，3-双加氧酶抑制剂及其在药学中的用途
EP3941472B1 (en) Crystalline and amorphous forms of-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2 <ns1:i>h</ns1:i>?-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
TWI535724B (zh) 埃克替尼磷酸鹽的新晶型及其用途
CN111892536A (zh) 取代的喹啉甲酰胺类化合物及其用途
WO2025256556A1 (zh) Protac嵌合化合物的固体形式、其制备方法、药物组合物和用途
CN104470929B (zh) 埃克替尼的晶型及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121107